-
CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Therapy
Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial […]
-
CureDuchenne Appoints Brenda Wong, MD, as Chief Medical Advisor to Advance Research and Improve Care for Individuals with Duchenne and Becker
Newport Beach, Calif., May 21, 2025 — CureDuchenne, a global nonprofit committed to finding and funding […]
-
Satellos reports data from their Phase 1b study
Satellos Biosciences announced their Phase 1b results from their open-label study with SAT-3247, which aims […]
-
How to Manage Stress and Fear in Uncertain Times
People in the neuromuscular disease community are hearing many different reports about policy and funding […]
-
Satellos Announces Positive Functional Data from Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne
Satellos Bioscience Inc. has announced encouraging data from the company’s Phase 1b open-label study of […]
-
Investigational gene therapy shows benefits in two boys with DMD
An investigational gene therapy called GNT0004 has demonstrated sustained stabilization of motor function at up to […]
-
Florida Signs Duchenne Newborn Screening into Law
We are delighted to share exciting news for the Duchenne community: Governor Ron DeSantis has […]
-
MDA Conference Grants Support Resources to the Community
The Muscular Dystrophy Association (MDA) provides a significant number of research grants each year to […]
-
How my fight for inclusive access to a soccer stadium paid off
As a Duchenne muscular dystrophy survivor, I’ve spent much of my life on the outside […]
-
NHL All-Star Troy Terry and Wife Dani to Host CureDuchenne Golf Shootout on September 12–13, Continuing a Legacy of Impact for Duchenne Muscular Dystrophy
Event Has Raised Over $6.3 Million to Date, Advancing Lifesaving Research and Therapies for Individuals […]
